NCT06907875: An ongoing trial by Epicrispr Biotechnologies, Inc.
This trial is ongoing. It must report results 5 years, 11 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06907875 |
|---|---|
| Title | A Phase 1/2 Open-label Dose-escalation Study to Evaluate the Safety, Tolerability, and Biological Activity of EPI-321, an AAVrh74-delivered Epigenetic Editing Therapy in Adult FSHD Patients |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | May 8, 2025 |
| Completion date | March 31, 2031 |
| Required reporting date | March 30, 2032, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | March 26, 2026 |
| Days late | None |